[Use of enerion in psychovegetative syndrome with pronounced asthenia].
Enerion was used in the treatment of 40 patients with psychovegetative syndrome and asthenia. Before treatment, the patients have pronounced asthenia appearances, anxiety disorders, relevant autonomic disorders, mild depression and decrease of working capacity, attention concentration and memory. The treatment was conducted as monotherapy during 28 days with enerion dosage 400 mg/day. After treatment, expression of autonomic and asthenic disorders was reduced significantly, along with improvement of psychometric and neurophysiological indices. High efficacy of the medication was detected in 75% of the patients and moderate one--in 25%. The drug was well-tolerated.
Veĭn
A M
AM
Fedotova
A V
AV
Gordeev
S A
SA
D000293:Adolescent; D000328:Adult; D001247:Asthenia / Q000188:drug therapy* / Q000523:psychology; D002087:Butyrates / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D004220:Disulfides / Q000737:chemistry; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011602:Psychophysiologic Disorders / Q000188:drug therapy* / Q000523:psychology; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D013577:Syndrome; D013831:Thiamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use*; D016896:Treatment Outcome
D002087:Butyrates; D004220:Disulfides; D011619:Psychotropic Drugs; D013831:Thiamine